ClinicalTrials.gg
CompletedNCT02305446Updated Jan 5, 2016Results posted

Safety and Blood Donations in Adults Vaccinated With rMenB+OMV NZ.

A Phase 3 interventional study of Meningococcal (group B) multicomponent recombinant adsorbed vaccine in Meningitis, Meningococcal, Serogroup B, sponsored by Novartis. Completed at 1 site in Poland. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-01-05.

Sponsored by Novartis · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
55
Allocation
Not applicable
Ages
18 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing 4CMenB vaccine in Meningitis, Meningococcal — 1 open to participants now, 2 under way, none of them phase 3. 4CMenB vaccine · Meningitis, Meningococcal.

Enrollment
8th of 11
55 · median 250
Started
2014
the only one that year
Phase 3
3 of 11
none open now
Registered
7th of 11
by date
Lead sponsor
2 of 11
Novartis

Among the 11 studies testing 4CMenB vaccine in Meningitis, Meningococcal, this one is the 8th largest by enrollment, is the only one that started in 2014, is one of 3 in phase 3, and was the 7th registered.

Meningitis, Meningococcal

125 studies on the registry are indexed under Meningitis, Meningococcal; 10 are open to participants now.

Browse Meningitis, Meningococcal studies →

Open to participants now

1 of the 11 studies testing 4CMenB vaccine in Meningitis, Meningococcal is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About 4CMenB vaccine

4CMenB vaccine: first FDA approval 2014 (Trumenba). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 5 Meningitis, Meningococcal studies recruiting now, none set no upper age limit and 5 stop at 75 or younger; 4 take children under 18; 5 take healthy volunteers.

This study: 18 Years to 50 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing 4CMenB vaccine in Meningitis, Meningococcal, or all of them as a file.
02

Study summary

The purpose of this trial is to assess the safety of a Meningococcal Group B Vaccine and to collect blood donation. Sera panel obtained from blood donations will be used as a control to measure the immunoresponse to the Meningococcal Group B Vaccine in other studies.

03

Conditions studied

  • Meningitis, Meningococcal, Serogroup B
04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Individuals of 18 through 50 years of age on the day of ;
  2. Individuals who had voluntarily given written informed consent after the nature of the study had been explained according to local regulatory requirements, prior to study entry;
  3. Individuals who could comply with study procedures including follow-up;
  4. Males, females of non- or females of childbearing potential who are using an effective method.

Exclusion criteria

Exclusion Criteria:

  1. Progressive, unstable or uncontrolled clinical conditions;
  2. , including allergy, to any component of vaccines or medical equipment whose use is foreseen in this study;
  3. Abnormal function of the immune system;
  4. Chronic clinical significant conditions;
  1. Been administered any group B meningococcal vaccine at any time prior to ; 5. Current or previous, confirmed or suspected disease caused by N.meningitidis.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
55 participants (actual)

Study arms

  • Experimental
    rMenB+OMV NZ

    Subjects who received two doses of rMenB+OMV NZ according to a 0, 2-month schedule

    Biological: Meningococcal (group B) multicomponent recombinant adsorbed vaccine

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Subjects Reporting Unsolicited Adverse Events (AEs).

    Safety was assessed as the number of the subjects who reported unsolicited AEs following vaccination.

    Time frame: From day 1 to day 7 after each vaccination (Vaccination 1: Day 1 to Day 7; Vaccination 2: Day 61 to Day 67)

Other outcomes

  1. Number of Adult Volunteers Whose Blood Can be Used as a Reference in Serum Bactericidal Activity (SBA) Test.

    The number of identified healthy adult volunteers with pre and postvaccination blood donations were summarized to establish a control sera panel to be used as a reference in SBA test.

    Time frame: Study day 1 blood sample was drawn between day -5 and day 1. Postvaccination 2 blood sample was drawn between day 23 and day 37 postvaccination 2.

07

Results

Posted Nov 1, 2015

Participant flow

Subjects will be enrolled at one site in Poland from December 2014 to February 2015.

Participant flow — Overall Study
MilestonerMenB+OMV NZ
Started55
Completed54
Not completed1
Withdrew: Adverse event1

Outcome measures

PrimaryNumber of Subjects Reporting Unsolicited Adverse Events (AEs).

Safety was assessed as the number of the subjects who reported unsolicited AEs following vaccination.

Time frame:
From day 1 to day 7 after each vaccination (Vaccination 1: Day 1 to Day 7; Vaccination 2: Day 61 to Day 67)
Reported as:
Number · Subjects
Number of Subjects Reporting Unsolicited Adverse Events (AEs).
SubjectsrMenB+OMV NZ
Any Serious Adverse Events (SAEs) (vaccination 1)0
Any Serious Adverse Events (SAEs) (vaccination 2)0
At least possibly related SAEs (vaccination 1)0
At least possibly related SAEs (vaccination 2)0
AEs leading to premature withdrawal (vaccination1)0
AEs leading to premature withdrawal (vaccination2)0
Medically attended AEs (vaccination 1)0
Medically attended AEs (vaccination 2)0
AESIs (AEs of Special Interest) (vaccination 1)0
AESIs (AEs of Special Interest) (vaccination 2)0
Other pre-specifiedNumber of Adult Volunteers Whose Blood Can be Used as a Reference in Serum Bactericidal Activity (SBA) Test.

The number of identified healthy adult volunteers with pre and postvaccination blood donations were summarized to establish a control sera panel to be used as a reference in SBA test.

Time frame:
Study day 1 blood sample was drawn between day -5 and day 1. Postvaccination 2 blood sample was drawn between day 23 and day 37 postvaccination 2.
Reported as:
Number · Participants
Number of Adult Volunteers Whose Blood Can be Used as a Reference in Serum Bactericidal Activity (SBA) Test.
ParticipantsrMenB+OMV NZ
Study Day 1 Blood Sample55
Postvaccination 2 Blood Sample50

Adverse events

Collected over Safety was assessed from the day of first vaccination (Day 1) until and inclusive the day of study termination (pre-planned at Day 91).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
rMenB+OMV NZ—1/55 (1.8%)0/55 (0%)
Most frequent serious events
Most frequent serious events
EventrMenB+OMV NZ
MULTIPLE SCLEROSISNervous system disorders1/55

Baseline characteristics

Age, Continuous
Age, Continuous(YEARS)rMenB+OMV NZ
Mean27.2 ± 6.932
Sex: Female, Male
Sex: Female, Male(Participants)rMenB+OMV NZ
Female27
Male28
08

Study locations

1 site
  • 01, Novartis Investigational Site
    Krakow, Poland
09

References and documents

Publications

  • Maritan M, Cozzi R, Lo Surdo P, Veggi D, Bottomley MJ, Malito E. Crystal structures of human Fabs targeting the Bexsero meningococcal vaccine antigen NHBA. Acta Crystallogr F Struct Biol Commun. 2017 Jun 1;73(Pt 6):305-314. doi: 10.1107/S2053230X17006021. Epub 2017 May 11. PubMed 28580917 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2014, a primary completion of Apr 2015 and a completion of Apr 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2015, 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 20, 2014
First posted
Dec 2, 2014
Start
Dec 2014
Primary completionActual
Apr 2015
CompletionActual
Apr 2015
Results first posted
Nov 1, 2015
Last update
Jan 5, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 5, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02305446
Lead sponsor
Novartis
Responsible party
Sponsor
First posted
Dec 2, 2014
Start date
Dec 2014
Primary completion
Apr 2015
Completion
Apr 2015
Results posted
Nov 1, 2015
Last update
Jan 5, 2016

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: 4CMenB vaccine

Start the discussion